Semaglutide Eligibility Across All Current Indications for US Adults

Ivy Shi; Sadiya S Khan; Robert W Yeh; Jennifer E Ho; Issa J Dahabreh; Dhruv S Kazi

doi:10.1001/jamacardio.2024.4657

Semaglutide Eligibility Across All Current Indications for US Adults

JAMA Cardiol. 2025 Jan 1;10(1):96-98. doi: 10.1001/jamacardio.2024.4657.

Authors

Ivy Shi^{1

2}, Sadiya S Khan^{3

4}, Robert W Yeh^{1

5}, Jennifer E Ho⁵, Issa J Dahabreh^{1

6

7

8}, Dhruv S Kazi^{1

5}

Affiliations

¹ Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.
² Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.
³ Department of Medicine and Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
⁴ Associate Editor, JAMA Cardiology.
⁵ Division of Cardiology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.
⁶ Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
⁷ Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
⁸ CAUSALab, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

No abstract available

Plain language summary

This cross-sectional study uses National Health and Nutrition Examination Survey data to examine the number of US adults eligible for semaglutide across all current indications.